The Association between <i>BRAF</i><sup>V600E</sup> Mutation and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Chinese Population: A Meta-analysis_West China Medical Journal

Authors：

 YangJing , YanShuping , GongYanping , ZhuJingqiang , LiZhihui ,  GongRixiang

Department of Thyroid and Breast Surgery,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P. R. China;

Corresponding author：

GongRixiang, Email: gongrixiang@scu.edu.cn

Keywords：

BRAF^V600E; Papillary thyroid carcinoma; Clinicopathologic characteristics; Meta-analysis

DOI：

10.7507/1002-0179.201600127

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the frequency of BRAF^V600E mutation and the association between BRAF^V600Emutation and clinicopathologic characteristics of papillary thyroid carcinoma (PTC) in Chinese population by Meta-analysis. Methods The relevant published studies before January 2014 were reviewed according to the defined selection criteria using the PubMed,Embase,VIP,China Biology Medicine Database,Wanfang and China Knowledge Resource Integrated Database. The effect sizes of outcome parameters were estimated by odds ratio (OR) or weighted mean difference with a 95% confidence interval (CI). The quality of the included trials was assessed and Meta-analyses were conducted by RevMan 5.1 software. Results The study included 46 studies with a total of 5 831 patients. The prevalence of BRAF^V600E mutation ranged from 25% to 83%,with an overall prevalence of 54.6%. The clinicopathologic characteristics of 5 542 patients were analyzed. There were statistical significances in association between BRAF^V600E mutation and the presence of classical type [OR=2.30,95%CI (1.32,4.01),P=0.003],follicular type [OR=0.44,95%CI (0.23,0.86),P=0.02],extrathyroidal extension [OR=2.18,95%CI (1.83,2.59),P<0.00001],multifocality [OR=1.31,95%CI (1.07,1.60),P=0.009],lymphocytic thyroiditis [OR=0.31,95%CI (0.23,0.42),P<0.00001],lymph node metastasis [OR=1.95,95%CI (1.40,2.72),P<0.000 1],advanced TNM stage [OR=2.41,95%CI (2.01,2.88),P<0.00001] and recurrence [OR=3.22,95%CI (2.04,5.09),P<0.00001],but the correlation of BRAF^V600E mutation was not significant with gender,mean age,mean tumor size,age being ≥45 years,tumor size being ≥10 mm,tall cell type,and distant metastases (P>0.05). Conclusion In Chinese patients,PTC with BRAF^V600E mutation has more aggressive clinicopathologic characteristics than that without BRAF^V600E mutation. The BRAF^V600E mutation may be used as an important prognostic marker for patients with PTC.

Citation： YangJing, YanShuping, GongYanping, ZhuJingqiang, LiZhihui, GongRixiang. The Association between BRAF^V600E Mutation and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Chinese Population: A Meta-analysis. West China Medical Journal, 2016, 31(3): 467-479. doi: 10.7507/1002-0179.201600127 Copy

1.	Xing M. BRAF mutation in thyroid cancer[J]. Endocr Relat Cancer, 2005, 12(2):245-262.
2.	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
3.	3 Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005[M/OL]. Bethesda:National Cancer Institute, 2007:907.[2010-12-24]. http://seer.cancer.gov/csr/1975_2005/.
4.	Schlumberger M, Pacini F. Prognostic factors[M]//Schlumberger M, Pacini F. Thyroid tumor. Paris:Nucleon Editions, 2003:111-125.
5.	Witt RL. Initial surgical management of thyroid cancer[J]. Surg Oncol Clin N Am, 2008, 17(1):71-91.
6.	Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid[J]. Endocr J, 2009, 56(2):177-192.
7.	Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer[J]. Nature, 2002, 417(6892):949-954.
8.	Deluca AM, Srinivas A, Alani RM. BRAF kinase in melanoma development and progression[J]. Expert Rev Mol Med, 2008, 10(1):e6.
9.	Min HS, Lee C, Jung KC. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population[J]. J Korean Med Sci, 2013, 28(4):534-541.
10.	Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer[J]. Ann Surg, 2007, 246(3):466-470; discussion 470-471.
11.	Kim TH, Park YJ, Lim JA, et al. The association of the BRAF^V600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer:a meta-analysis[J]. Cancer, 2012, 118(7):1764-1773.
12.	Liu X, Yan K, Lin X, et al. The association between BRAF^V600E mutation and pathological features in PTC[J]. Eur Arch Otorhinolaryngol, 2014, 271(11):3041-3052.
13.	Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF^V600E mutation in papillary carcinomas of the thyroid:a meta-analysis[J]. Cancer, 2007, 110(1):38-46.
14.	Li C, Lee KC, Schneider EB, et al. BRAF^V600E mutation and its association with clinicopathological features of papillary thyroid cancer:a meta-analysis[J]. J Clin Endocrinol Metab, 2012, 97(12):4559-4570.
15.	Xing MZ, Clark D, Guan HX, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer[J]. J Clin Oncol, 2009, 27(18):2977-2982.
16.	Kim SJ, Lee KE, Myong JP, et al. BRAF^V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012, 36(2):310-317.
17.	Costa AM, Herrero A, Fresno MF, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2008, 68(4):618-634.
18.	龚艳萍, 龚日祥, 杨敬, 等. 甲状腺乳头状癌BRAF基因突变与临床病理特征间的关系及临床意义[J]. 四川大学学报:医学版, 2013, 44(4):662-665.
19.	Nam JK, Jung CK, Song BJ, et al. Is the BRAF^V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer?[J]. Am J Surg, 2012, 203(4):436-441.
20.	Kim YS, Kim JS, Bae JS, et al. Clinical implication of the BRAF^V600E mutation in papillary thyroid carcinoma[J]. World J Surg Oncol, 2013, 11:99.
21.	曾宪涛, 刘慧, 陈曦, 等. Meta分析系列之四:观察性研究的质量评价工具[J]. 中国循证心血管医学杂志, 2011, 8(4):297-299.
22.	龚日祥, 周扬, 罗书画, 等. 甲状腺乳头状癌BRAF基因突变的检测及临床意义[J]. 中华医学遗传学杂志, 2009, 26(3):310-313.
23.	Liu RT, Chen YJ, Chou FF, et al. No correlation between BRAF^V600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan[J]. Clin Endocrinol (Oxf), 2005, 63(4):461-466.
24.	Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2009, 94(5):1612-1617.
25.	Shao H, Yu X, Wang C, et al. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer[J]. Endocrine, 2014, 46(2):285-291.
26.	尹香利, 张国昌, 李锋, 等. MASA-PCR检测甲状腺乳头状癌中BRAF^V600E点突变的研究[J]. 石河子大学学报:自然科学版, 2005, 23(5):551-555.
27.	Gu LQ, Li FY, Zhao L, et al. BRAF^V600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma[J]. Thyroid, 2009, 19(4):347-354.
28.	Gong RX, Gong YP, Yang J, et al. Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid carcinoma using multiplex allele-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography[J]. Genet Mol Res, 2013, 12(4):4990-4997.
29.	Gao WL, Wie LL, Chao YG, et al. Prognostic prediction of BRAF^V600E and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas[J]. Clin Lab, 2012, 58(9/10):919-926.
30.	Wang W, Zhao W, Wang H, et al. Poorer prognosis and higher prevalence of BRAF^V600E mutation in synchronous bilateral papillary thyroid carcinoma[J]. Ann Surg Oncol, 2012, 19(1):31-36.
31.	Jiang W, Wang W, Fu F, et al. A more sensitive platform for the detection of low-abundance BRAF^V600E mutations[J]. Mol Cell Biochem, 2012, 366(1/2):49-58.
32.	Zheng X, Xia T, Lin L, et al. BRAF^V600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma:experience of 512 cases at a clinical center in China[J]. World J Surg Oncol, 2012, 10:104.
33.	Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF^V600E mutational status in high aggressive papillary thyroid microcarcinoma[J]. Ann Surg Oncol, 2009, 16(2):240-245.
34.	Wang Y, Ji M, Wang W, et al. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer[J]. Endocr Relat Cancer, 2008, 15(1):183-190.
35.	Zhou YL, Liu C, Dai XX, et al. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas[J]. Med Oncol, 2012, 29(5):3360-3366.
36.	Huang Y, Liao D, Pan L, et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAF^V600E mutation[J]. Eur J Endocrinol, 2013, 168(5):675-681.
37.	Guan H, Ji M, Hou P, et al. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer[J]. Cancer, 2008, 113(2):247-255.
38.	宝荣, 邵华, 成建新, 等. 甲状腺乳头状癌中DNA修复基因hMLH1的甲基化与BRAF突变的关系[J]. 重庆医学, 2010, 39(5):519-521.
39.	曹艳, 石光清, 向谷良. 甲状腺癌中BRAF^V600E突变的表达及意义[J]. 放射免疫学杂志, 2011, 24(5):599-600, 封3.
40.	代文莉, 崔邦平, 胡涛, 等. 甲状腺乳头状癌BRAF突变与初始治疗疗效的关系[J]. 现代肿瘤医学, 2013, 21(3):504-506.
41.	戴咏玲, 李北宁, 努尔曼·麦麦提祖农, 等. BRAF基因突变与甲状腺乳头状癌淋巴结转移相关性的研究[J]. 中国医学创新, 2011, 8(31):29-30.
42.	李小强, 张惠箴, 蒋智铭, 等. 甲状腺乳头状癌中BRAF基因的表达及意义[J]. 临床与实验病理学杂志, 2012, 28(9):991-995.
43.	梁军, 赵丹, 梁智勇, 等. 甲状腺乳头状癌合并淋巴细胞性甲状腺炎临床病理生物学特征分析[J]. 中华肿瘤防治杂志, 2013, 20(17):1331-1335.
44.	刘超, 戴璇璇, 周毅力, 等. 甲状腺乳头状癌mir-221表达与BRAF突变的相关性研究[J]. 中国肿瘤, 2012, 21(4):298-302.
45.	卢军峰, 解乃昌, 姬逸男. BRAF^V600E基因突变及p27蛋白表达与甲状腺乳头状癌颈淋巴结转移的关系[J]. 河北医学, 2011, 17(6):711-714.
46.	牛卫, 罗月球, 陈丽荣. 甲状腺乳头状癌BRAF基因突变及表达的临床意义研究[J]. 实用肿瘤杂志, 2008, 23(6):519-523.
47.	潘杰, 赵世华, 赵鹏, 等. 甲状腺乳头状癌BRAF T1799A基因突变与血小板衍生生长因子关系的研究[J]. 现代肿瘤医学, 2008, 16(9):1469-1472.
48.	濮亚斌, 李刚强. 甲状腺乳头状癌中BRAF^V600E基因异常的临床意义[J]. 实用癌症杂志, 2013, 28(3):246-248.
49.	王炜, 黎向红, 章银辉, 等. BRAF基因V600E突变在甲状腺病变中的表达[J]. 中华肿瘤杂志, 2011, 33(5):354-357.
50.	夏婷婷, 胡传祥, 赵静, 等. 甲状腺乳头状癌BRAF^V600E突变分析[J]. 中国肿瘤临床, 2012, 39(11):785-787.
51.	易文君, 钟德玝, 邹琼燕. BRAF基因突变与甲状腺乳头状癌的相关性[J]. 中南大学学报:医学版, 2012, 37(4):370-373.
52.	Jing FJ, Liang J, Liang ZY, et al. BRAF^V600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma[J]. Chin Med J (Engl), 2013, 126(16):3013-3018.
53.	臧循雄, 陈建武, 林宏献, 等. 甲状腺乳头状癌BRAF^V600E基因突变的研究[J]. 现代实用医学, 2009, 21(12):1296-1297, 1306, 封2.
54.	张薇, 王翠芳, 关海霞. 甲状腺乳头状癌中M2型丙酮酸激酶的表达及其与BRAF基因突变的关系[J]. 肿瘤, 2013, 33(4):350-354.
55.	郑丽, 胡向阳. Galectin-3、CK19、HBME-1表达和BRAF基因突变在甲状腺乳头状癌中的意义[J]. 安徽西科大学学报, 2013, 48(4):401-405.
56.	周睿, 王伟斌, 王海勇, 等. RET/PTC、p53及BRAF在甲状腺乳头状癌中的表达和意义[J]. 浙江医学, 2010, 32(6):942-944.
57.	朱晓丽, 周晓燕, 朱雄增. 甲状腺乳头状癌中BRAF^V600E点突变与RET/PTC融合基因的检测[J]. 中华病理学杂志, 2005, 34(5):270-274.
58.	左庆瑶, 高燕明, 刘宝岳, 等. 乳头状甲状腺癌BRAF^V600E突变的表达和意义[J]. 中华内科杂志, 2009, 48(5):412-413.
59.	郑向前, 夏婷婷, 林琳, 等. 多灶性甲状腺乳头状癌BRAF^V600E基因突变及临床生物学特性分析[J]. 中国肿瘤临床, 2011, 38(21):1326-1329.
60.	亓龙, 左娣, 王辉, 等. REGγ、p53、NOTCH1和BRAF在甲状腺癌中的表达及其临床意义[J]. 华东师范大学学报:自然科学版, 2012(6):89-95.
61.	赵洪涛, 赵春清, 张彬, 等. 甲状腺乳头状癌中CD44v6 BRAF和Rasp21的表达[J]. 中国肿瘤临床与康复, 2012, 19(4):310-312.
62.	高卫利, 王伟斌, 王浩浩, 等. 甲状腺乳头状癌BRAF^V600E突变和钠/碘转运体表达的研究[J]. 中华普通外科杂志, 2013, 28(5):378-381.
63.	江晓燊, 解乃昌. 甲状腺乳头状癌BRAF^V600E突变蛋白质的表达及意义[J]. 广东医学, 2013, 34(6):931-933.
64.	李志锋, 刘进忠, 孙鹏娟, 等. HIF-1α、BRAF、S100A6在甲状腺乳头状癌中的表达及其临床意义[J]. 临床外科杂志, 2013, 21(6):436-438.
65.	刘友忠, 于洋, 赵翠, 等. 甲状腺乳头状癌合并桥本甲状腺炎的临床生物学特性分析[J]. 中华普通外科杂志, 2013, 28(4):256-258.
66.	王昊, 卢瑞春, 董娴宁, 等. BRAF基因V600E突变与Ⅰ~Ⅱ期乳头状甲状腺癌临床病理特征及预后的相关性分析[J]. 临床肿瘤学杂志, 2013, 18(12):1100-1103.
67.	运新伟, 刘友忠, 高明. 甲状腺乳头状癌合并桥本甲状腺炎的临床特征与BRAF^V600E基因突变的相关性分析[J]. 中华内分泌代谢杂志, 2013, 29(11):931-934.
68.	钟文昭, 吴一龙, 谷力加. Review Manager(RevMan)——临床医生通向Meta分析的桥梁[J]. 循证医学, 2003, 3(4):234-246.
69.	Frasca F, Nucera C, Pellegriti G, et al. BRAF^V600E mutation and the biology of papillary thyroid cancer[J]. Endocr Relat Cancer, 2008, 15(1):191-205.
70.	Stanojevic B, Dzodic R, Saenko V, et al. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia[J]. Endocr J, 2011, 58(5):381-393.
71.	Elisei R, Ugolini C, Viola D, et al. BRAF^V600E mutation and outcome of patients with papillary thyroid carcinoma:a 15-year median follow-up study[J]. J Clin Endocrinol Metab, 2008, 93(10):3943-3949.
72.	Sykorova V, Dvorakova S, Ryska A, et al. BRAF^V600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic[J]. J Endocrinol Invest, 2010, 33(5):318-324.
73.	Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population:its lack of correlation with high-risk clinicopathological features and disease-free survival of patients[J]. Endocr J, 2009, 56(1):89-97.
74.	Kurtulmus N, Duren M, Ince U, et al. BRAF^V600E mutation in Turkish patients with papillary thyroid cancer:strong correlation with indicators of tumor aggressiveness[J]. Endocrine, 2012, 42(2):404-410.
75.	Kim SJ, Ke LE, Myong JP, et al. BRAF^V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012, 36(2):310-317.
76.	Jo YS, Li S, Song JH, et al. Influence of the BRAF^V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2006, 91(9):3667-3670.
77.	Kim KH, Kang DW, Kim SH, et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population[J]. Yonsei Med J, 2004, 45(5):818-821.
78.	Finkelstein A, Levy GH, Hui P, et al. Papillary thyroid carcinomas with and without BRAF^V600E mutations are morphologically distinct[J]. Histopathology, 2012, 60(7):1052-1059.
79.	Lee KC, Li C, Schneider EB, et al. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?[J]. Surgery, 2012, 152(6):977-982.
80.	Morris LG, Shaha AR, Tuttle RM, et al. Tall-cell variant of papillary thyroid carcinoma:a matched-pair analysis of survival[J]. Thyroid, 2010, 20(2):153-158.
81.	Leung AK, Chow SM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma[J]. Laryngoscope, 2008, 118(1):32-38.
82.	Lang BH, Lo CY, Chan WF, et al. Classical and follicular variant of papillary thyroid carcinoma:a comparative study on clinicopathologic features and long-term outcome[J]. World J Surg, 2006, 30(5):752-758.
83.	Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2012, 91(5):274-286.
84.	Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF^V600E mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis[J]. Thyroid, 2009, 19(2):137-141.
85.	Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5):764-773; discussion 773-775.
86.	Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis:a meta-analysis[J]. Eur J Endocrinol, 2013, 168(3):343-349.
87.	Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2006, 65(3):364-368.
88.	Lee JI, Jang HW, Kim SW, et al. BRAF^V600E mutation in fine-needle aspiration aspirates:association with poorer prognostic factors in larger papillary thyroid carcinomas[J]. Head Neck, 2013, 35(4):548-553.
89.	Ulisse S, Baldini E, Sorrenti S, et al. In papillary thyroid carcinoma BRAF^V600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval[J]. Clin Endocrinol (Oxf), 2012, 77(5):780-786.
90.	Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5):418-428.
91.	Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment:initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group[J]. Cancer, 1998, 83(5):1012-1021.
92.	Xing M. BRAF mutation in papillary thyroid cancer:pathogenic role, molecular bases, and clinical implications[J]. Endocr Rev, 2007, 28(7):742-762.
93.	Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis[J]. J Clin Endocrinol Metab, 2005, 90(10):5723-5729.
94.	Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma[J]. Surgery, 2008, 144(6):1070-1077; discussion 1077-1078.
95.	Lupi C, Giannini R, Ugolini C, et al. Association of BRAF^V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2007, 92(11):4085-4090.

1. Xing M. BRAF mutation in thyroid cancer[J]. Endocr Relat Cancer, 2005, 12(2):245-262.
2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
3. 3 Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005[M/OL]. Bethesda:National Cancer Institute, 2007:907.[2010-12-24]. http://seer.cancer.gov/csr/1975_2005/.
4. Schlumberger M, Pacini F. Prognostic factors[M]//Schlumberger M, Pacini F. Thyroid tumor. Paris:Nucleon Editions, 2003:111-125.
5. Witt RL. Initial surgical management of thyroid cancer[J]. Surg Oncol Clin N Am, 2008, 17(1):71-91.
6. Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid[J]. Endocr J, 2009, 56(2):177-192.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer[J]. Nature, 2002, 417(6892):949-954.
8. Deluca AM, Srinivas A, Alani RM. BRAF kinase in melanoma development and progression[J]. Expert Rev Mol Med, 2008, 10(1):e6.
9. Min HS, Lee C, Jung KC. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population[J]. J Korean Med Sci, 2013, 28(4):534-541.
10. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer[J]. Ann Surg, 2007, 246(3):466-470; discussion 470-471.
11. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF^V600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer:a meta-analysis[J]. Cancer, 2012, 118(7):1764-1773.
12. Liu X, Yan K, Lin X, et al. The association between BRAF^V600E mutation and pathological features in PTC[J]. Eur Arch Otorhinolaryngol, 2014, 271(11):3041-3052.
13. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF^V600E mutation in papillary carcinomas of the thyroid:a meta-analysis[J]. Cancer, 2007, 110(1):38-46.
14. Li C, Lee KC, Schneider EB, et al. BRAF^V600E mutation and its association with clinicopathological features of papillary thyroid cancer:a meta-analysis[J]. J Clin Endocrinol Metab, 2012, 97(12):4559-4570.
15. Xing MZ, Clark D, Guan HX, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer[J]. J Clin Oncol, 2009, 27(18):2977-2982.
16. Kim SJ, Lee KE, Myong JP, et al. BRAF^V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012, 36(2):310-317.
17. Costa AM, Herrero A, Fresno MF, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2008, 68(4):618-634.
18. 龚艳萍, 龚日祥, 杨敬, 等. 甲状腺乳头状癌BRAF基因突变与临床病理特征间的关系及临床意义[J]. 四川大学学报:医学版, 2013, 44(4):662-665.
19. Nam JK, Jung CK, Song BJ, et al. Is the BRAF^V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer?[J]. Am J Surg, 2012, 203(4):436-441.
20. Kim YS, Kim JS, Bae JS, et al. Clinical implication of the BRAF^V600E mutation in papillary thyroid carcinoma[J]. World J Surg Oncol, 2013, 11:99.
21. 曾宪涛, 刘慧, 陈曦, 等. Meta分析系列之四:观察性研究的质量评价工具[J]. 中国循证心血管医学杂志, 2011, 8(4):297-299.
22. 龚日祥, 周扬, 罗书画, 等. 甲状腺乳头状癌BRAF基因突变的检测及临床意义[J]. 中华医学遗传学杂志, 2009, 26(3):310-313.
23. Liu RT, Chen YJ, Chou FF, et al. No correlation between BRAF^V600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan[J]. Clin Endocrinol (Oxf), 2005, 63(4):461-466.
24. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2009, 94(5):1612-1617.
25. Shao H, Yu X, Wang C, et al. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer[J]. Endocrine, 2014, 46(2):285-291.
26. 尹香利, 张国昌, 李锋, 等. MASA-PCR检测甲状腺乳头状癌中BRAF^V600E点突变的研究[J]. 石河子大学学报:自然科学版, 2005, 23(5):551-555.
27. Gu LQ, Li FY, Zhao L, et al. BRAF^V600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma[J]. Thyroid, 2009, 19(4):347-354.
28. Gong RX, Gong YP, Yang J, et al. Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid carcinoma using multiplex allele-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography[J]. Genet Mol Res, 2013, 12(4):4990-4997.
29. Gao WL, Wie LL, Chao YG, et al. Prognostic prediction of BRAF^V600E and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas[J]. Clin Lab, 2012, 58(9/10):919-926.
30. Wang W, Zhao W, Wang H, et al. Poorer prognosis and higher prevalence of BRAF^V600E mutation in synchronous bilateral papillary thyroid carcinoma[J]. Ann Surg Oncol, 2012, 19(1):31-36.
31. Jiang W, Wang W, Fu F, et al. A more sensitive platform for the detection of low-abundance BRAF^V600E mutations[J]. Mol Cell Biochem, 2012, 366(1/2):49-58.
32. Zheng X, Xia T, Lin L, et al. BRAF^V600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma:experience of 512 cases at a clinical center in China[J]. World J Surg Oncol, 2012, 10:104.
33. Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF^V600E mutational status in high aggressive papillary thyroid microcarcinoma[J]. Ann Surg Oncol, 2009, 16(2):240-245.
34. Wang Y, Ji M, Wang W, et al. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer[J]. Endocr Relat Cancer, 2008, 15(1):183-190.
35. Zhou YL, Liu C, Dai XX, et al. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas[J]. Med Oncol, 2012, 29(5):3360-3366.
36. Huang Y, Liao D, Pan L, et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAF^V600E mutation[J]. Eur J Endocrinol, 2013, 168(5):675-681.
37. Guan H, Ji M, Hou P, et al. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer[J]. Cancer, 2008, 113(2):247-255.
38. 宝荣, 邵华, 成建新, 等. 甲状腺乳头状癌中DNA修复基因hMLH1的甲基化与BRAF突变的关系[J]. 重庆医学, 2010, 39(5):519-521.
39. 曹艳, 石光清, 向谷良. 甲状腺癌中BRAF^V600E突变的表达及意义[J]. 放射免疫学杂志, 2011, 24(5):599-600, 封3.
40. 代文莉, 崔邦平, 胡涛, 等. 甲状腺乳头状癌BRAF突变与初始治疗疗效的关系[J]. 现代肿瘤医学, 2013, 21(3):504-506.
41. 戴咏玲, 李北宁, 努尔曼·麦麦提祖农, 等. BRAF基因突变与甲状腺乳头状癌淋巴结转移相关性的研究[J]. 中国医学创新, 2011, 8(31):29-30.
42. 李小强, 张惠箴, 蒋智铭, 等. 甲状腺乳头状癌中BRAF基因的表达及意义[J]. 临床与实验病理学杂志, 2012, 28(9):991-995.
43. 梁军, 赵丹, 梁智勇, 等. 甲状腺乳头状癌合并淋巴细胞性甲状腺炎临床病理生物学特征分析[J]. 中华肿瘤防治杂志, 2013, 20(17):1331-1335.
44. 刘超, 戴璇璇, 周毅力, 等. 甲状腺乳头状癌mir-221表达与BRAF突变的相关性研究[J]. 中国肿瘤, 2012, 21(4):298-302.
45. 卢军峰, 解乃昌, 姬逸男. BRAF^V600E基因突变及p27蛋白表达与甲状腺乳头状癌颈淋巴结转移的关系[J]. 河北医学, 2011, 17(6):711-714.
46. 牛卫, 罗月球, 陈丽荣. 甲状腺乳头状癌BRAF基因突变及表达的临床意义研究[J]. 实用肿瘤杂志, 2008, 23(6):519-523.
47. 潘杰, 赵世华, 赵鹏, 等. 甲状腺乳头状癌BRAF T1799A基因突变与血小板衍生生长因子关系的研究[J]. 现代肿瘤医学, 2008, 16(9):1469-1472.
48. 濮亚斌, 李刚强. 甲状腺乳头状癌中BRAF^V600E基因异常的临床意义[J]. 实用癌症杂志, 2013, 28(3):246-248.
49. 王炜, 黎向红, 章银辉, 等. BRAF基因V600E突变在甲状腺病变中的表达[J]. 中华肿瘤杂志, 2011, 33(5):354-357.
50. 夏婷婷, 胡传祥, 赵静, 等. 甲状腺乳头状癌BRAF^V600E突变分析[J]. 中国肿瘤临床, 2012, 39(11):785-787.
51. 易文君, 钟德玝, 邹琼燕. BRAF基因突变与甲状腺乳头状癌的相关性[J]. 中南大学学报:医学版, 2012, 37(4):370-373.
52. Jing FJ, Liang J, Liang ZY, et al. BRAF^V600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma[J]. Chin Med J (Engl), 2013, 126(16):3013-3018.
53. 臧循雄, 陈建武, 林宏献, 等. 甲状腺乳头状癌BRAF^V600E基因突变的研究[J]. 现代实用医学, 2009, 21(12):1296-1297, 1306, 封2.
54. 张薇, 王翠芳, 关海霞. 甲状腺乳头状癌中M2型丙酮酸激酶的表达及其与BRAF基因突变的关系[J]. 肿瘤, 2013, 33(4):350-354.
55. 郑丽, 胡向阳. Galectin-3、CK19、HBME-1表达和BRAF基因突变在甲状腺乳头状癌中的意义[J]. 安徽西科大学学报, 2013, 48(4):401-405.
56. 周睿, 王伟斌, 王海勇, 等. RET/PTC、p53及BRAF在甲状腺乳头状癌中的表达和意义[J]. 浙江医学, 2010, 32(6):942-944.
57. 朱晓丽, 周晓燕, 朱雄增. 甲状腺乳头状癌中BRAF^V600E点突变与RET/PTC融合基因的检测[J]. 中华病理学杂志, 2005, 34(5):270-274.
58. 左庆瑶, 高燕明, 刘宝岳, 等. 乳头状甲状腺癌BRAF^V600E突变的表达和意义[J]. 中华内科杂志, 2009, 48(5):412-413.
59. 郑向前, 夏婷婷, 林琳, 等. 多灶性甲状腺乳头状癌BRAF^V600E基因突变及临床生物学特性分析[J]. 中国肿瘤临床, 2011, 38(21):1326-1329.
60. 亓龙, 左娣, 王辉, 等. REGγ、p53、NOTCH1和BRAF在甲状腺癌中的表达及其临床意义[J]. 华东师范大学学报:自然科学版, 2012(6):89-95.
61. 赵洪涛, 赵春清, 张彬, 等. 甲状腺乳头状癌中CD44v6 BRAF和Rasp21的表达[J]. 中国肿瘤临床与康复, 2012, 19(4):310-312.
62. 高卫利, 王伟斌, 王浩浩, 等. 甲状腺乳头状癌BRAF^V600E突变和钠/碘转运体表达的研究[J]. 中华普通外科杂志, 2013, 28(5):378-381.
63. 江晓燊, 解乃昌. 甲状腺乳头状癌BRAF^V600E突变蛋白质的表达及意义[J]. 广东医学, 2013, 34(6):931-933.
64. 李志锋, 刘进忠, 孙鹏娟, 等. HIF-1α、BRAF、S100A6在甲状腺乳头状癌中的表达及其临床意义[J]. 临床外科杂志, 2013, 21(6):436-438.
65. 刘友忠, 于洋, 赵翠, 等. 甲状腺乳头状癌合并桥本甲状腺炎的临床生物学特性分析[J]. 中华普通外科杂志, 2013, 28(4):256-258.
66. 王昊, 卢瑞春, 董娴宁, 等. BRAF基因V600E突变与Ⅰ~Ⅱ期乳头状甲状腺癌临床病理特征及预后的相关性分析[J]. 临床肿瘤学杂志, 2013, 18(12):1100-1103.
67. 运新伟, 刘友忠, 高明. 甲状腺乳头状癌合并桥本甲状腺炎的临床特征与BRAF^V600E基因突变的相关性分析[J]. 中华内分泌代谢杂志, 2013, 29(11):931-934.
68. 钟文昭, 吴一龙, 谷力加. Review Manager(RevMan)——临床医生通向Meta分析的桥梁[J]. 循证医学, 2003, 3(4):234-246.
69. Frasca F, Nucera C, Pellegriti G, et al. BRAF^V600E mutation and the biology of papillary thyroid cancer[J]. Endocr Relat Cancer, 2008, 15(1):191-205.
70. Stanojevic B, Dzodic R, Saenko V, et al. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia[J]. Endocr J, 2011, 58(5):381-393.
71. Elisei R, Ugolini C, Viola D, et al. BRAF^V600E mutation and outcome of patients with papillary thyroid carcinoma:a 15-year median follow-up study[J]. J Clin Endocrinol Metab, 2008, 93(10):3943-3949.
72. Sykorova V, Dvorakova S, Ryska A, et al. BRAF^V600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic[J]. J Endocrinol Invest, 2010, 33(5):318-324.
73. Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population:its lack of correlation with high-risk clinicopathological features and disease-free survival of patients[J]. Endocr J, 2009, 56(1):89-97.
74. Kurtulmus N, Duren M, Ince U, et al. BRAF^V600E mutation in Turkish patients with papillary thyroid cancer:strong correlation with indicators of tumor aggressiveness[J]. Endocrine, 2012, 42(2):404-410.
75. Kim SJ, Ke LE, Myong JP, et al. BRAF^V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012, 36(2):310-317.
76. Jo YS, Li S, Song JH, et al. Influence of the BRAF^V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2006, 91(9):3667-3670.
77. Kim KH, Kang DW, Kim SH, et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population[J]. Yonsei Med J, 2004, 45(5):818-821.
78. Finkelstein A, Levy GH, Hui P, et al. Papillary thyroid carcinomas with and without BRAF^V600E mutations are morphologically distinct[J]. Histopathology, 2012, 60(7):1052-1059.
79. Lee KC, Li C, Schneider EB, et al. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?[J]. Surgery, 2012, 152(6):977-982.
80. Morris LG, Shaha AR, Tuttle RM, et al. Tall-cell variant of papillary thyroid carcinoma:a matched-pair analysis of survival[J]. Thyroid, 2010, 20(2):153-158.
81. Leung AK, Chow SM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma[J]. Laryngoscope, 2008, 118(1):32-38.
82. Lang BH, Lo CY, Chan WF, et al. Classical and follicular variant of papillary thyroid carcinoma:a comparative study on clinicopathologic features and long-term outcome[J]. World J Surg, 2006, 30(5):752-758.
83. Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2012, 91(5):274-286.
84. Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF^V600E mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis[J]. Thyroid, 2009, 19(2):137-141.
85. Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5):764-773; discussion 773-775.
86. Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis:a meta-analysis[J]. Eur J Endocrinol, 2013, 168(3):343-349.
87. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2006, 65(3):364-368.
88. Lee JI, Jang HW, Kim SW, et al. BRAF^V600E mutation in fine-needle aspiration aspirates:association with poorer prognostic factors in larger papillary thyroid carcinomas[J]. Head Neck, 2013, 35(4):548-553.
89. Ulisse S, Baldini E, Sorrenti S, et al. In papillary thyroid carcinoma BRAF^V600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval[J]. Clin Endocrinol (Oxf), 2012, 77(5):780-786.
90. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5):418-428.
91. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment:initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group[J]. Cancer, 1998, 83(5):1012-1021.
92. Xing M. BRAF mutation in papillary thyroid cancer:pathogenic role, molecular bases, and clinical implications[J]. Endocr Rev, 2007, 28(7):742-762.
93. Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis[J]. J Clin Endocrinol Metab, 2005, 90(10):5723-5729.
94. Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma[J]. Surgery, 2008, 144(6):1070-1077; discussion 1077-1078.
95. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF^V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2007, 92(11):4085-4090.

West China Medical Journal

The Association between BRAF^V600E Mutation and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Chinese Population: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

West China Medical Journal

The Association between BRAFV600E Mutation and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Chinese Population: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

The Association between BRAF^V600E Mutation and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Chinese Population: A Meta-analysis